Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient with Locally Advanced Rectal Cancer
Inclusion Criteria
- The patient must have signed and dated an Institutional Review Board (IRB)-approved consent form that conforms to federal and institutional guidelines
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Diagnosis of adenocarcinoma of the rectum with the major portion of the tumor intact; Note: prior to randomization, the investigator must specify and document each of the following: * Distance of the lowest tumor margin from the anal verge; and * Intent for sphincter sparing or non-sphincter sparing surgical resection according to the primary surgeon; and * The majority of the untreated tumor must be < 12 cm from the anal verge or below the peritoneal reflection as determined by the treating surgeon
- The tumor must be clinically determined to be locally advanced stage II or stage III rectal cancer, and must also meet any ONE of the following criteria: * Distal location (as defined by measurement on magnetic resonance imaging [MRI], transrectal ultrasound [ERUS]/pelvic computed tomography [CT] [with IV contrast] scan or palpable on digital rectal examination [DRE]): cT3-4 =< 5 cm from the anal verge, any N * Bulky: any cT4 or evidence that the tumor is adjacent to (defined as within 3 mm of) the mesorectal fascia on MRI or ERUS/pelvic CT (with IV contrast) scan * High risk for metastatic disease with 4 or more regional lymph nodes (cN2); clinical nodal or "cN" status for eligibility includes the total number of nodes (N2 = 4 or more) in the mesorectal and superior rectal stations measuring >= 1.0 cm in any axis on cross sectional or endoscopic imaging; Note: nodes must measure 1.0 cm or greater to be considered positive for this eligibility requirement * Not a candidate for sphincter-sparing surgical resection prior to neoadjuvant therapy (as planned by the primary surgeon) ** Note: clinical stage of the primary tumor and nodes may be determined locally by rectal endoscopic ultrasound or pelvic MRI (pelvic MRI is strongly preferred); CT scan with IV contrast is acceptable provided there is evidence of T4 and/or N2 disease
- Patients must have the ability to swallow and retain oral medication
- Absolute neutrophil count (ANC) must be >= 1200/mm^3 (within 28 days before randomization)
- Platelet count must be >= 100,000/mm^3 (within 28 days before randomization)
- Hemoglobin must be >= 10 g/dL (within 28 days before randomization)
- Total bilirubin must be =< ULN (upper limit of normal) for the lab unless the patient has a bilirubin elevation > ULN to 1.5 x ULN due to Gilbert’s disease or similar syndrome involving slow conjugation of bilirubin (within 28 days before randomization)
- Alkaline phosphatase must be =< 3 x ULN for the lab (within 28 days before randomization)
- Aspartate aminotransferase (AST) must be =< 3 x ULN for the lab (within 28 days before randomization); * Note: if alanine aminotransferase (ALT) is performed instead of AST (per institution's standard practice), the ALT value must be =< 3 x ULN; if both were performed, the AST must also be =< 3 x ULN; if AST and/or ALT is >= ULN but =< 3 x ULN, serologic testing for hepatitis B and C must be performed and results for viral infection must be negative
- Serum creatinine =< ULN for the lab and measured or calculated creatinine clearance > 60 mL/min (within 28 days before randomization)
- Serum potassium, magnesium, and calcium levels within 28 days before randomization must be within normal limits (WNL) for the lab
- International normalized ratio of prothrombin time (INR) within 28 days before randomization must be =< ULN for the lab; patients who are therapeutically treated with an agent such as warfarin may participate if they are on a stable dose and no underlying abnormality in coagulation parameters exists per medical history
- Patients with acquired immunodeficiency syndrome (AIDS-related illnesses) or known human immunodeficiency virus (HIV) disease must: * Have a cluster of differentiation (CD)4 count >= 200 cells/uL within 30 days before beginning study therapy * Be off all antiretroviral therapy (prophylaxis/treatment) more than 60 days before beginning study therapy, and * Have no evidence of opportunistic infections
- Pregnancy test (urine or serum beta-human chorionic gonadotropin [HCG]) done within 72 hours before randomization must be negative (for women of childbearing potential only); if urine pregnancy results are positive or cannot be confirmed as negative, a serum pregnancy test will be required
Exclusion Criteria
- Rectal cancer histology other than adenocarcinoma (i.e., sarcoma, lymphoma, squamous cell carcinoma, mucosal melanoma, etc.)
- Definitive clinical or radiologic evidence of metastatic disease; required imaging studies must have been performed within 28 days prior to randomization; Note: Distant clinical staging to exclude patients with overt metastatic disease is determined by: * Chest: CT scan (preferred); chest x-ray posterioranterior (PA) and lateral (acceptable); or positron emission tomography (PET) scan (acceptable) * Abdomen: CT scan with IV contrast (preferred); or MRI (acceptable) * Pelvis: MRI (preferred) or CT scan with IV contrast (acceptable) ** (It is recommended that the same imaging tests that are performed before randomization be used at follow-up time points; Note: CT scans of the abdomen and pelvis must be performed with IV contrast)
- History of prior invasive rectal malignancy, regardless of disease-free interval
- Cardiac disease that would preclude the use of any of the drugs included in the GI002 treatment regimen; this includes but is not limited to: * Clinically unstable cardiac disease, including unstable atrial fibrillation, symptomatic bradycardia, unstable congestive heart failure, active myocardial ischemia, or indwelling temporary pacemaker * Ventricular tachycardia or supraventricular tachycardia that requires treatment with class Ia antiarrhythmic drugs (e.g., quinidine, procainamide, disopyramide) or class III antiarrhythmic drug (e.g., sotalol, amiodarone, dofetilide); use of other antiarrhythmic drugs is permitted * Second- or third-degree atrioventricular (AV) block unless treated with a permanent pacemaker * Complete left bundle branch block (LBBB) * History of long QT syndrome * Corrected QT (QTc) >= 450 ms
- Sensory or motor neuropathy >= grade 2
- History of, or any evidence of active, non-infectious pneumonitis
- Active inflammatory bowel disease (i.e., patients requiring current medical interventions or who are symptomatic) or have a history of abdominal surgery or other medical condition that may, in the opinion of the treating physician, interfere with gastrointestinal motility or absorption
- Active autoimmune disease that has required systemic treatment within the past 2 years (i.e., with use of modifying agents, corticosteroids, or immunosuppressive drugs); replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
- History of active TB (Bacillus tuberculosis)
- Active or chronic infection requiring systemic therapy
- Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study therapy; the use of physiologic doses of corticosteroids may be approved after consultation with the study principal investigator (PI)
- Active seizure disorder uncontrolled by medication
- Any antineoplastic therapy for this cancer before randomization
- Synchronous colon cancer
- Other invasive cancer within 5 years before randomization; exceptions are colonic polyps, non-melanoma skin cancer or carcinoma-in-situ of the cervix
- Antineoplastic therapy (e.g. chemotherapy or targeted therapy) for other invasive cancer within 5 years before randomization; (for the purposes of this study, hormonal therapy is not considered chemotherapy)
- Prior treatment with an investigational compound being tested in this study (e.g., poly ADP ribose polymerase [PARP] inhibitor, anti-PD-1, anti-PD-L1, or anti-PD-L2)
- Receipt of live vaccination within 28 days before randomization; seasonal flu vaccines that do not contain live virus are permitted
- Major surgery within 4 weeks before randomization
- Any therapeutic pelvic radiation
- Known homozygous DPD (dihydro pyrimidine dehydrogenase) deficiency
- Any of the following because this study involves agents that have known or potential genotoxic or mutagenic, and teratogenic effects: * Pregnant women * Nursing women who are unwilling to discontinue nursing * Men or women of childbearing potential who are unwilling to employ adequate contraception (e.g., hormonal or barrier method of birth control; abstinence) for the duration of study treatment and for 4 months after the last dose of study therapy
- Co-morbid illnesses or other concurrent disease that, in the judgement of the clinician obtaining informed consent, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens or prevent required follow-up
Alabama
Birmingham
Mobile
Alaska
Fairbanks
Arizona
Gilbert
Scottsdale
Tucson
Arkansas
Ft. Smith
Hot Springs
Jonesboro
Little Rock
California
Anaheim
Antioch
Arroyo Grande
Auburn
Bakersfield
Berkeley
Burlingame
Cameron Park
Castro Valley
Chico
Corona
Duarte
Dublin
Fremont
Fresno
La Jolla
Lancaster
Los Angeles
Marysville
Modesto
Mountain View
Novato
Oakland
Orange
Palo Alto
Rancho Cordova
Redwood City
Richmond
Riverside
Rohnert Park
Roseville
Sacramento
San Diego
San Francisco
San Jose
San Leandro
San Marcos
San Rafael
Santa Clara
Santa Rosa
South Pasadena
South San Francisco
Stockton
Sunnyvale
Truckee
Upland
Vacaville
Vallejo
Walnut Creek
Whittier
Colorado
Aurora
Boulder
Colorado Springs
Denver
Englewood
Fort Collins
Grand Junction
Greeley
Lakewood
Littleton
Longmont
Loveland
Pueblo
Thornton
Wheat Ridge
Connecticut
Guilford
Hartford
Meriden
New Britain
New Haven
North Haven
Norwich
Trumbull
Waterford
Delaware
Lewes
Newark
Rehoboth Beach
Seaford
Florida
Gainesville
Jacksonville
Orlando
Georgia
Atlanta
Gainesville
Savannah
Hawaii
Aiea
Honolulu
Lihue
Idaho
Boise
Caldwell
Meridian
Post Falls
Illinois
Arlington Heights
Aurora
Bloomington
Carbondale
Carterville
Centralia
Chicago
Danville
Decatur
Effingham
Galesburg
Geneva
Harvey
Lake Forest
Mattoon
Maywood
Mount Vernon
New Lenox
O'Fallon
Ottawa
Pekin
Peoria
Peru
Princeton
Rockford
Silvis
Springfield
Swansea
Urbana
Warrenville
Indiana
Evansville
Fort Wayne
Goshen
Indianapolis
Michigan City
Mishawaka
Mooresville
Newburgh
Richmond
South Bend
Iowa
Ames
Cedar Rapids
Clive
Davenport
Des Moines
Iowa City
West Des Moines
Kansas
Dodge City
El Dorado
Garden City
Great Bend
Kansas City
Lawrence
Olathe
Overland Park
Pittsburg
Salina
Topeka
Wellington
Westwood
Wichita
Winfield
Kentucky
Lexington
Louisville
Louisiana
Baton Rouge
Covington
Houma
New Orleans
Maine
Bangor
Brewer
Maryland
Baltimore
Salisbury
Massachusetts
Boston
Pittsfield
Michigan
Adrian
Ann Arbor
Battle Creek
Bay City
Brownstown
Clarkston
Clinton Township
Dearborn
Detroit
Farmington Hills
Flint
Grand Rapids
Jackson
Kalamazoo
Lansing
Lapeer
Livonia
Mount Clemens
Mount Pleasant
Muskegon
Niles
Novi
Owosso
Petoskey
Pontiac
Port Huron
Reed City
Royal Oak
Saginaw
Saint Joseph
Southfield
Traverse City
Troy
Warren
West Bloomfield
Wyoming
Minnesota
Bemidji
Brainerd
Burnsville
Coon Rapids
Deer River
Detroit Lakes
Duluth
Edina
Fergus Falls
Fosston
Fridley
Hibbing
Maple Grove
Maplewood
Minneapolis
Monticello
Park Rapids
Robbinsdale
Rochester
Saint Cloud
Saint Louis Park
Saint Paul
Sandstone
Shakopee
Stillwater
Virginia
Waconia
Willmar
Woodbury
Mississippi
Grenada
New Albany
Oxford
Southhaven
Missouri
Ballwin
Bolivar
Bonne Terre
Cape Girardeau
Creve Coeur
Jefferson City
Joplin
Kansas City
Lee's Summit
Rolla
Saint Joseph
Saint Louis
Saint Peters
Sainte Genevieve
Springfield
Sullivan
Sunset Hills
Montana
Billings
Bozeman
Butte
Great Falls
Kalispell
Missoula
Nebraska
Grand Island
Kearney
Lincoln
Omaha
Scottsbluff
Nevada
Henderson
Las Vegas
Reno
New Hampshire
Lebanon
New Jersey
Englewood
Moorestown
Mount Holly
New Brunswick
Somerville
Teaneck
Voorhees
New Mexico
Albuquerque
Santa Fe
New York
Bay Shore
Bronx
Glens Falls
Lake Success
Manhasset
Middletown
New Hyde Park
New York
Rochester
Staten Island
Syracuse
North Carolina
Albemarle
Asheville
Charlotte
Concord
Huntersville
Matthews
Monroe
Raleigh
Shelby
Winston-Salem
North Dakota
Bismarck
Fargo
Jamestown
Ohio
Akron
Beachwood
Beavercreek
Canton
Centerville
Chardon
Cincinnati
Cleveland
Columbus
Dayton
Elyria
Findlay
Franklin
Greenville
Kettering
Maumee
Mentor
Middleburg Heights
Parma
Ravenna
Sandusky
Springfield
Sylvania
Toledo
Troy
Wadsworth
West Chester
Westlake
Oklahoma
Lawton
Oklahoma City
Oregon
Gresham
Portland
Pennsylvania
Abington
Allentown
Bethlehem
Broomall
Chadds Ford
Danville
Dunmore
East Stroudsburg
Erie
Glen Mills
Jefferson Hills
Lewisburg
Lewistown
Monroeville
Philadelphia
Pittsburgh
Selinsgrove
Sellersville
West Reading
Wilkes-Barre
Willow Grove
Wynnewood
Puerto Rico
Bayamon
Manati
San Juan
South Carolina
Anderson
Boiling Springs
Charleston
Gaffney
Greenville
Greer
Rock Hill
Seneca
Spartanburg
Union
South Dakota
Aberdeen
Sioux Falls
Tennessee
Chattanooga
Collierville
Germantown
Memphis
Nashville
Texas
Bryan
Dallas
Galveston
Houston
League City
Lubbock
Temple
Utah
Cedar City
Logan
Murray
Ogden
Provo
Riverton
Saint George
Salt Lake City
Vermont
Berlin
Burlington
Saint Johnsbury
Virginia
Hampton
Norfolk
Richmond
Washington
Auburn
Bellevue
Bremerton
Burien
Federal Way
Gig Harbor
Kennewick
Kirkland
Mount Vernon
Puyallup
Renton
Seattle
Spokane
Tacoma
Vancouver
Wenatchee
Yakima
West Virginia
Bridgeport
Charleston
Morgantown
Parkersburg
Wheeling
Wisconsin
Ashland
Burlington
Eau Claire
Fond Du Lac
Germantown
Grafton
Green Bay
Johnson Creek
Kenosha
Madison
Marinette
Marshfield
Menomonee Falls
Milwaukee
Minocqua
Mukwonago
New Richmond
Oconomowoc
Oshkosh
Racine
Rice Lake
Sheboygan
Stevens Point
Summit
Two Rivers
Waukesha
Wausau
Wauwatosa
West Allis
West Bend
Weston
PRIMARY OBJECTIVE:
I. To demonstrate an absolute improvement in neoadjuvant rectal cancer (NAR) score for the experimental regimen as compared to concurrently randomized control patients.
SECONDARY OBJECTIVES:
I. To compare overall survival (OS).
II. To compare disease-free survival (DFS).
III. To compare the rate of pathologic complete response (pCR) (nodes and tumor).
IV. To compare the rate of sphincter preservation.
TERTIARY OBJECTIVES:
I. To compare the proportion of patients who have a tumor resection overall, conditional on beginning induction chemotherapy, and conditional on beginning chemoradiotherapy.
II. To compare time from initiation of chemoradiotherapy to surgery in the subset of patients with tumor resection.
EXPLORATORY OBJECTIVES:
I. To estimate the rate of disease progression during chemotherapy (prior to chemoradiation).
II. To compare the rate of clinical complete response rate (cCR).
III. To compare the rate of negative circumferential margin.
IV. To compare the rate of completion of all cycles of neoadjuvant chemotherapy.
V. To compare the rate of completion of full course of chemoradiation.
VI. To compare the toxicity and safety between interventions.
VII. To explore the correlative molecular predictors of response and distant failure.
VIII. To explore the relationship between radiographic findings and pathologic outcomes.
OUTLINE: Patients are randomized to 1 of 3 treatment arms.
ARM I: Patients receive mFOLFOX6 regimen consisting of oxaliplatin intravenously (IV) over 2 hours, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 46-48 hours on days 1-2. Treatment repeats every 2 weeks for 8 cycles in the absence of disease progression or unacceptable toxicity. 3-4 weeks after last does of mFOLFOX6 patient undergo radiation therapy (RT) and receive capecitabine orally (PO) twice daily (BID) Monday-Friday for 5 weeks in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive mFOLFOX6 regimen consisting of oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 46-48 hours on days 1-2. Treatment repeats every 2 weeks for 8 cycles in the absence of disease progression or unacceptable toxicity. 3-4 weeks after last does of mFOLFOX6 patient undergo RT and receive capecitabine PO BID and veliparib PO BID Monday-Friday for 5 weeks in the absence of disease progression or unacceptable toxicity.
ARM III: Patients receive mFOLFOX6 regimen consisting of oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 46-48 hours on days 1-2. Treatment repeats every 2 weeks for 8 cycles in the absence of disease progression or unacceptable toxicity. 3-4 weeks after last does of mFOLFOX6 patient undergo RT and receive capecitabine PO BID Monday-Friday for 5 weeks. They also receive pembrolizumab IV over 30 minutes every 3 weeks beginning on day 1 of RT for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days and every 6 months for up to 3 years.
Trial Phase Phase II
Trial Type Treatment
Lead Organization
NRG Oncology
Principal Investigator
Thomas J. George
- Primary ID NRG-GI002
- Secondary IDs NCI-2016-00222, s17-00197
- Clinicaltrials.gov ID NCT02921256